The Major Infectious Diseases in the World — To Treat or Not to Treat?
- 19 July 2001
- journal article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 345 (3) , 208-210
- https://doi.org/10.1056/nejm200107193450310
Abstract
In this issue of the Journal, Tahaoğlu and coworkers report on their experience in treating a cohort of patients infected with strains of Mycobacterium tuberculosis that are resistant to powerful antituberculosis drugs. Tuberculosis caused by strains that are resistant to at least isoniazid and rifampin is, by convention, termed “multidrug-resistant tuberculosis.”1 The authors of this report work in a referral center in Turkey that has available a full complement of clinical, laboratory, and surgical services, including multidrug treatment regimens given for 18 to 24 months, resources for the management of side effects, adjuvant surgery when necessary, and full financial and . . .Keywords
This publication has 4 references indexed in Scilit:
- The Treatment of Multidrug-Resistant Tuberculosis in TurkeyNew England Journal of Medicine, 2001
- Global Trends in Resistance to Antituberculosis DrugsNew England Journal of Medicine, 2001
- Standard Short-Course Chemotherapy for Drug-Resistant TuberculosisJAMA, 2000
- Global Surveillance for Antituberculosis-Drug Resistance, 1994–1997New England Journal of Medicine, 1998